

BÃ©nÃ©dicte Lebrun-Vignes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/802308/publications.pdf>

Version: 2024-02-01

60
papers

5,354
citations

218677

26
h-index

144013

57
g-index

62
all docs

62
docs citations

62
times ranked

5732
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2018, 4, 1721.	7.1	1,625
2	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology</i> , The, 2018, 19, 1579-1589.	10.7	742
3	Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. <i>Lancet</i> , The, 2018, 391, 933.	13.7	618
4	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		237
5	Cardiovascular Toxicities Associated With Ibrutinib. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1667-1678.	2.8	169
6	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	9.4	145
7	Immune Checkpoint Inhibitor-Associated Myositis. <i>Circulation</i> , 2018, 138, 743-745.	1.6	139
8	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	30.7	133
9	Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. <i>Circulation</i> , 2020, 142, 2443-2455.	1.6	121
10	Hematologic Complications of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 584-588.	3.7	103
11	Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. <i>British Journal of Dermatology</i> , 2013, 169, 1041-1048.	1.5	99
12	Uses of pharmacovigilance databases: An overview. <i>Therapie</i> , 2020, 75, 591-598.	1.0	92
13	Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. <i>Diabetes Care</i> , 2018, 41, e150-e151.	8.6	82
14	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586.	5.8	80
15	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. <i>Oncologist</i> , 2020, 25, 696-701.	3.7	73
16	Androgenic Effects on Ventricular Repolarization. <i>Circulation</i> , 2019, 140, 1070-1080.	1.6	67
17	A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 238-246.	1.2	56
18	Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 504-508.	0.9	54

#	ARTICLE	IF	CITATIONS
19	Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. <i>British Journal of Dermatology</i> , 2012, 166, 1333-1341.	1.5	52
20	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. <i>Scientific Reports</i> , 2022, 12, 7140.	3.3	45
21	Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. <i>Nature Communications</i> , 2022, 13, 25.	12.8	44
22	Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. <i>European Journal of Cancer</i> , 2021, 148, 36-47.	2.8	42
23	Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 570-579.	2.4	41
24	Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. <i>European Heart Journal</i> , 2021, 42, 3915-3928.	2.2	38
25	Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. <i>Heart</i> , 2018, 104, 1859-1863.	2.9	37
26	Characterizing drug-induced capillary leak syndromes using the World Health Organization Vigibase. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 433-436.	2.9	32
27	Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal) <i>Tj ETQq1 1 0.784314 rgBT /Over Dermatology</i> , 2020, 182, 618-624.	1.5	29
28	Checkpoint inhibitor-associated immune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e68-e68.	0.9	27
29	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 9-21.	1.6	27
30	Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 331-338.	2.4	25
31	Immune checkpoint inhibitor-associated hypophysitis World Health Organisation Vigibase report analysis. <i>European Journal of Cancer</i> , 2019, 113, 10-13.	2.8	23
32	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. <i>Pharmaceuticals</i> , 2020, 13, 325.	3.8	23
33	Characterization of auto-immune hepatitis associated with the use of anti-TNF± agents: An analysis of 389 cases in Vigibase. <i>Autoimmunity Reviews</i> , 2020, 19, 102460.	5.8	21
34	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. <i>European Respiratory Journal</i> , 2020, 55, 2000038.	6.7	19
35	Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 699-712.	1.6	18
36	Severe cutaneous adverse reactions due to inappropriate medication use. <i>British Journal of Dermatology</i> , 2018, 179, 329-336.	1.5	17

#	ARTICLE	IF	CITATIONS
37	Drug-induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis. British Journal of Clinical Pharmacology, 2019, 85, 2540-2546.	2.4	17
38	Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. European Journal of Cancer, 2019, 123, 112-115.	2.8	17
39	Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals. Journal of the American Academy of Dermatology, 2017, 77, 98-104.e1.	1.2	15
40	Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. European Journal of Dermatology, 2017, 27, 271-274.	0.6	11
41	Solid organ transplant rejection associated with immune-checkpoint inhibitors. Annals of Oncology, 2020, 31, 543-544.	1.2	11
42	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. Journal of Autoimmunity, 2020, 111, 102454.	6.5	11
43	Reporting of immune checkpoint inhibitor-associated myocarditis â Authors' reply. Lancet, The, 2018, 392, 384-385.	13.7	7
44	Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database. Autoimmunity Reviews, 2021, 20, 102705.	5.8	7
45	Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. British Journal of Dermatology, 2019, 180, 666-667.	1.5	6
46	Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study. European Journal of Endocrinology, 2021, 184, 437-444.	3.7	6
47	Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: âspecificâ patterns in a series of 192 patients. British Journal of Dermatology, 2022, 187, 615-617.	1.5	6
48	Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review. Frontiers in Pharmacology, 2020, 11, 619649.	3.5	5
49	Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study. Therapie, 2021, 76, 695-703.	1.0	5
50	Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination. Journal of Neurology, 2022, 269, 5647-5650.	3.6	5
51	Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports. Therapie, 2021, , .	1.0	4
52	Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1569-1576.	2.4	4
53	Safety of Topical Corticosteroid Use During Pregnancy. Archives of Dermatology, 2012, 148, 525.	1.4	3
54	Sipuleucelâ associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database. ESC Heart Failure, 2021, 8, 3360-3368.	3.1	3

#	ARTICLE	IF	CITATIONS
55	Lookalike and soundalike drugs: a potential cause of cutaneous adverse reactions to drugs. <i>British Journal of Dermatology</i> , 2019, 181, 626-627.	1.5	2
56	Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. <i>Annales D'Endocrinologie</i> , 2021, 82, 132-133.	1.4	2
57	Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 434-441.	1.9	2
58	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1344-1346.	3.8	0
59	Answer to Tahri et al. Â«Â«Retinoid Hyperostosis, an overlooked cause of atypical sacroiliac pain in young patients: A pharmacovigilance surveyÂ»Â». <i>Joint Bone Spine</i> 2020. doi: 10.1016/j.jbspin.2020.06.023. <i>Joint Bone Spine</i> , 2020, 87, 523-524.	1.6	0
60	Tratamientos tÃ©picos del acnÃ© y de la rosÃ¡cea. <i>EMC - DermatologÃ­a</i> , 2018, 52, 1-10.	0.1	0